Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
PR Newswire
CHENGDU, China, May 21, 2026
Sacituzumab tirumotecan (sac-TMT)(佳泰莱®) plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1 positive advanced NSCLC: Results from the randomized, controlled, registrational Phase III OptiTROP-Lung05 study (Abstract #8506)Efficacy and safety of lunbotinib fumarate (A400/EP0031,宁泰莱®[1]), a next-generation selective RET inhibitor (SRI), from a pivotal registrational Phase Ⅱ study in patients with advanced RET-fusion positive NSCLC (Abstract #8505)CHENGDU, China, May 21, 2026 /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 29 to June 2, local time. Two registrational studies of the trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT)(佳泰莱®) and the next‑generation selective rearranged during transfection (RET) inhibitor lunbotinib fumarate (A400/EP0031,宁泰莱®) from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) have been selected for oral presentation session on Lung Cancer – Non-Small Cell Metastatic. The full text of the related abstracts were published on the ASCO official website[2] on May 21, 2026, local time. Key highlights are summarized as follows:
